One million people receive experimental Chinese COVID-19 vaccine

One million people receive experimental Chinese COVID-19 vaccine

Also Read | COVID-19 Vaccine Sputnik V Showed "Very High" Effectiveness in Phase 3 Trial, Says Russian Health Official.

Days after US-based biotechnology Moderna's vaccine showed 94.5 per cent efficacy in fight against COVID-19 infection, the Company's Chief Executive said that they will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered. The Serum Institute of India is conducting the phase-three trial of the Oxford-AstraZeneca COVID-19 vaccine, while Bharat Biotech and ICMR has already started the phase-three trail of the indigenously developed COVAXIN jab.

Sinopharm's chairman told media this week that almost a million people have now received their vaccine for emergency use, though he did not provide a specific figure. However, no adverse reactions have been reported by the state, the company or the trial participants, said Sinopharm.

The first efficacy data from the late-stage trials may come in the next few weeks, the Lancet said.

Numerous trials are taking place overseas, as China has largely brought the virus under control within its borders.

A Chinese Foreign Ministry spokesman Zhao Lijian told a media briefing on Wednesday that five Chinese vaccine candidates are under clinical trials in countries, including the UAE, Brazil, Pakistan and Peru, and phase one and phase two clinical trials of some other vaccines are accelerated.

The company claimed this week to be "leading the world in all aspects" of vaccine development, although it did not offer clinical evidence from ongoing trials.

Volunteers from a variety of age groups and backgrounds, including some of the thousands who have registered to be contacted about vaccine studies through the NHS COVID-19 Vaccine Research Registry, have begun taking part in the latest study at 17 National Institute for Health Research (NIHR) sites across the United Kingdom, including MFT.

Related Articles